Pathophysiology and treatment of hepatitis C infection

Journal of Pharmacy Practice

Volumn 12, Issue 5, 1999, Pages 391-400

  Krick, Stacie E ^a,b   Gwinn, Kimberly A ^a,b   Morgan, Douglas R ^c,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Wake Area Health Education Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Neonatology Services   (United States)

Author keywords

Hepatitis C virus (HCV); Interferon alpha; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CONSENSUS INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; VIRUS ISOLATION; VIRUS TRANSMISSION;

EID: 0033403007     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/089719009901200505     Document Type: Review

References (20)

1. Sharara AI, Hunt CM, and Hamilton JD. Hepatitis C. Ann Intern Med. 1996;125:658-668.
2. Lam NP. Hepatitis C: Natural history, diagnosis, and management. Am J Health-Syst Pharm. 1999;56:961-976.
3. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996;125: 634-639.
4. Centers for Disease Control and prevention. Recommendations for prevention and control of hepatitis C (HCV) infection and HCV-related disease. MMWR 1998;47(no. RR-19): 1-38.
5. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327: 369-373.
6. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with use of intravenous immune globulin. JAMA. 1996; 276(19):1563-1567.
7. Shakil AO, Conry C, Alter HJ, et al. Volunteer blood donors with antibody to HCV: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-337.
8. DiBisceglie AM. Hepatitis C. Lancet. 1998;351:351-356.
9. Management of Hepatitis C. National Institutes of Health Consensus Development Conference Statement. 1997 March 24-26;15(3): 1-41.
10. Lok ASF, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology. 1997;26(Suppl 1):48s-56s.
11. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998;27: 868.
12. Hoofnagle JH and DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997; 336(5):347-356.
13. Camma C, Giunta M, Pinzello G, et al. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomnized controlled trials. Am J Gastroenterol. 1999; 94:581-595.
14. Imperial J. Treatment of chronic hepatitis C virus infection: The end of an era. Am J Gastroenterol. 1999;94:555-556.
15. Maddrey WC. New approach for treatment of chronic hepatitis C: Pegylated interferon. Proceedings of Digestive Disease Week Conference; 1999 May 16: Orlando.
16. DiBisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995;123:897-903.
17. McHutchinson JG, Gordan SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
18. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
19. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339: 1493-1499.
20. Rebetron package insert. Kenilworth, NJ: Schering-Plough Corporation; 1998.